Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 101 entries
Sorted by: Best Match Show Resources per page
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Trial watch: Dendritic cell-based anticancer therapy.

Oncoimmunology

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941593
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell...

Cite
Bloy N, Pol J, Aranda F, et al. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014;3(11):e963424doi: 10.4161/21624011.2014.963424.
Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., Dhodapkar, M. V., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology, 3(11), e963424. https://doi.org/10.4161/21624011.2014.963424
Bloy, Norma, et al. "Trial watch: Dendritic cell-based anticancer therapy." Oncoimmunology vol. 3,11 (2014): e963424. doi: https://doi.org/10.4161/21624011.2014.963424
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. PMID: 25941593; PMCID: PMC4292311.
Copy Download .nbib Format: NLM
The immune landscape of human tumors: Implications for cancer immunotherapy.

Oncoimmunology

Bindea G, Mlecnik B, Angell HK, Galon J.
PMID: 24800163
Oncoimmunology. 2014 Jan 01;3(1):e27456. doi: 10.4161/onci.27456. Epub 2014 Jan 03.

Understanding the spontaneous immune response of cancer patients is critical for the design of efficient anticancer immunotherapies. The power of integrative tumor immunology approaches allowed for a comprehensive view of the immune system evolution in the course of tumor...

Cite
Bindea G, Mlecnik B, Angell HK, et al. The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology. 2014;3(1):e27456doi: 10.4161/onci.27456.
Bindea, G., Mlecnik, B., Angell, H. K., & Galon, J. (2014). The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology, 3(1), e27456. https://doi.org/10.4161/onci.27456
Bindea, Gabriela, et al. "The immune landscape of human tumors: Implications for cancer immunotherapy." Oncoimmunology vol. 3,1 (2014): e27456. doi: https://doi.org/10.4161/onci.27456
Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology. 2014 Jan 01;3(1):e27456. doi: 10.4161/onci.27456. Epub 2014 Jan 03. PMID: 24800163; PMCID: PMC4006852.
Copy Download .nbib Format: NLM
Intrinsic selectivity in capillary electrophoresis for chiral separations with dual cyclodextrin systems.

Analytical chemistry

Lelièvre F, Gareil P, Bahaddi Y, Galons H.
PMID: 21639191
Anal Chem. 1997 Feb 01;69(3):393-401. doi: 10.1021/ac960607r.

Defined as the ratio of the affinity factors of the analytes for a complexing agent, the intrinsic selectivity is representative of the very nature of the complexing agent. When more than one complexing agent are present in the background...

Cite
Lelièvre F, Gareil P, Bahaddi Y, et al. Intrinsic selectivity in capillary electrophoresis for chiral separations with dual cyclodextrin systems. Anal Chem. 1997;69(3):393-401doi: 10.1021/ac960607r.
Lelièvre, F., Gareil, P., Bahaddi, Y., & Galons, H. (1997). Intrinsic selectivity in capillary electrophoresis for chiral separations with dual cyclodextrin systems. Analytical chemistry, 69(3), 393-401. https://doi.org/10.1021/ac960607r
Lelièvre, F, et al. "Intrinsic selectivity in capillary electrophoresis for chiral separations with dual cyclodextrin systems." Analytical chemistry vol. 69,3 (1997): 393-401. doi: https://doi.org/10.1021/ac960607r
Lelièvre F, Gareil P, Bahaddi Y, Galons H. Intrinsic selectivity in capillary electrophoresis for chiral separations with dual cyclodextrin systems. Anal Chem. 1997 Feb 01;69(3):393-401. doi: 10.1021/ac960607r. PMID: 21639191.
Copy Download .nbib Format: NLM
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Oncoimmunology

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 23162757
Oncoimmunology. 2012 Sep 01;1(6):894-907. doi: 10.4161/onci.20931.

Toll-like receptors (TLRs) have first been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded RNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLRs have also been...

Cite
Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(6):894-907doi: 10.4161/onci.20931.
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology, 1(6), 894-907. https://doi.org/10.4161/onci.20931
Vacchelli, Erika, et al. "Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy." Oncoimmunology vol. 1,6 (2012): 894-907. doi: https://doi.org/10.4161/onci.20931
Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 Sep 01;1(6):894-907. doi: 10.4161/onci.20931. PMID: 23162757; PMCID: PMC3489745.
Copy Download .nbib Format: NLM
[Not Available].

Journal de chirurgie

Pagès F, Berger A, Zinzindohoué F, Kirilovsky A, Galon J, Fridman WH.
PMID: 22794075
J Chir (Paris). 2008 Dec;145(6):12S6-12S12. doi: 10.1016/S0021-7697(08)45002-0.

F. Pagès, A. Berger, F. Zinzindohoué, A. Kirilovsky, J. Galon, W.-H. Fridman Lymph node dissection is an integral part of the surgical resection of colon cancers; it completes the wide regional resection of tumor and it allows prognostic evaluation...

Cite
Pagès F, Berger A, Zinzindohoué F, et al. Implications immunologiques potentielles du curage ganglionnaire : Exemple du cancer colorectal. [Not Available]. J Chir (Paris). 2008;145(6):12S6-12S12doi: 10.1016/S0021-7697(08)45002-0.
Pagès, F., Berger, A., Zinzindohoué, F., Kirilovsky, A., Galon, J., & Fridman, W. H. (2008). Implications immunologiques potentielles du curage ganglionnaire : Exemple du cancer colorectal. [Not Available]. Journal de chirurgie, 145(6), 12S6-12S12. https://doi.org/10.1016/S0021-7697(08)45002-0
Pagès, F, et al. "Implications immunologiques potentielles du curage ganglionnaire : Exemple du cancer colorectal." [Not Available]. Journal de chirurgie vol. 145,6 (2008): 12S6-12S12. doi: https://doi.org/10.1016/S0021-7697(08)45002-0
Pagès F, Berger A, Zinzindohoué F, Kirilovsky A, Galon J, Fridman WH. Implications immunologiques potentielles du curage ganglionnaire : Exemple du cancer colorectal. [Not Available]. J Chir (Paris). 2008 Dec;145(6):12S6-12S12. doi: 10.1016/S0021-7697(08)45002-0. French. PMID: 22794075.
Copy Download .nbib Format: NLM
A finite difference method with periodic boundary conditions for simulations of diffusion-weighted magnetic resonance experiments in tissue.

Physics in medicine and biology

Russell G, Harkins KD, Secomb TW, Galons JP, Trouard TP.
PMID: 22297418
Phys Med Biol. 2012 Feb 21;57(4):N35-46. doi: 10.1088/0031-9155/57/4/N35. Epub 2012 Feb 01.

A new finite difference (FD) method for calculating the time evolution of complex transverse magnetization in diffusion-weighted magnetic resonance imaging and spectroscopy experiments is described that incorporates periodic boundary conditions. The new FD method relaxes restrictions on the allowable...

Cite
Russell G, Harkins KD, Secomb TW, et al. A finite difference method with periodic boundary conditions for simulations of diffusion-weighted magnetic resonance experiments in tissue. Phys Med Biol. 2012;57(4):N35-46doi: 10.1088/0031-9155/57/4/N35.
Russell, G., Harkins, K. D., Secomb, T. W., Galons, J. P., & Trouard, T. P. (2012). A finite difference method with periodic boundary conditions for simulations of diffusion-weighted magnetic resonance experiments in tissue. Physics in medicine and biology, 57(4), N35-46. https://doi.org/10.1088/0031-9155/57/4/N35
Russell, Greg, et al. "A finite difference method with periodic boundary conditions for simulations of diffusion-weighted magnetic resonance experiments in tissue." Physics in medicine and biology vol. 57,4 (2012): N35-46. doi: https://doi.org/10.1088/0031-9155/57/4/N35
Russell G, Harkins KD, Secomb TW, Galons JP, Trouard TP. A finite difference method with periodic boundary conditions for simulations of diffusion-weighted magnetic resonance experiments in tissue. Phys Med Biol. 2012 Feb 21;57(4):N35-46. doi: 10.1088/0031-9155/57/4/N35. Epub 2012 Feb 01. PMID: 22297418; PMCID: PMC6996935.
Copy Download .nbib Format: NLM
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Oncoimmunology

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 22934262
Oncoimmunology. 2012 Aug 01;1(5):699-716. doi: 10.4161/onci.20696.

Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known for their ability to activate the innate immune system in response to conserved microbial components such as lipopolysaccharide and double-stranded RNA. Accumulating evidence indicates that the function of...

Cite
Galluzzi L, Vacchelli E, Eggermont A, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(5):699-716doi: 10.4161/onci.20696.
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology, 1(5), 699-716. https://doi.org/10.4161/onci.20696
Galluzzi, Lorenzo, et al. "Trial Watch: Experimental Toll-like receptor agonists for cancer therapy." Oncoimmunology vol. 1,5 (2012): 699-716. doi: https://doi.org/10.4161/onci.20696
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 Aug 01;1(5):699-716. doi: 10.4161/onci.20696. PMID: 22934262; PMCID: PMC3429574.
Copy Download .nbib Format: NLM
Estimation of visceral fat in 9- to 13-year-old girls using dual-energy X-ray absorptiometry (DXA) and anthropometry.

Obesity science & practice

Lee V, Blew R, Hetherington-Rauth M, Blew D, Galons JP, Hagio T, Bea J, Lohman T, Going S.
PMID: 30338114
Obes Sci Pract. 2018 Sep 13;4(5):437-447. doi: 10.1002/osp4.297. eCollection 2018 Oct.

OBJECTIVES: Accumulation of visceral fat (VF) in children increases the risk of cardiovascular disease and type 2 diabetes, and measurement of VF in children using computed tomography and magnetic resonance imaging (MRI) is expensive. Dual-energy X-ray absorptiometry (DXA) may...

Cite
Lee V, Blew R, Hetherington-Rauth M, et al. Estimation of visceral fat in 9- to 13-year-old girls using dual-energy X-ray absorptiometry (DXA) and anthropometry. Obes Sci Pract. 2018;4(5):437-447doi: 10.1002/osp4.297.
Lee, V., Blew, R., Hetherington-Rauth, M., Blew, D., Galons, J. P., Hagio, T., Bea, J., Lohman, T., & Going, S. (2018). Estimation of visceral fat in 9- to 13-year-old girls using dual-energy X-ray absorptiometry (DXA) and anthropometry. Obesity science & practice, 4(5), 437-447. https://doi.org/10.1002/osp4.297
Lee, V, et al. "Estimation of visceral fat in 9- to 13-year-old girls using dual-energy X-ray absorptiometry (DXA) and anthropometry." Obesity science & practice vol. 4,5 (2018): 437-447. doi: https://doi.org/10.1002/osp4.297
Lee V, Blew R, Hetherington-Rauth M, Blew D, Galons JP, Hagio T, Bea J, Lohman T, Going S. Estimation of visceral fat in 9- to 13-year-old girls using dual-energy X-ray absorptiometry (DXA) and anthropometry. Obes Sci Pract. 2018 Sep 13;4(5):437-447. doi: 10.1002/osp4.297. eCollection 2018 Oct. PMID: 30338114; PMCID: PMC6180717.
Copy Download .nbib Format: NLM
Immunoscore and its introduction in clinical practice.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Galon J, Lanzi A.
PMID: 32107902
Q J Nucl Med Mol Imaging. 2020 Jun;64(2):152-161. doi: 10.23736/S1824-4785.20.03249-5. Epub 2020 Feb 27.

Current cancer classification is based on intrinsic tumor parameters such as characteristic of tumor cells, tumor progression, tumor invasion and the presence of distant metastases, as summarized by the AJCC/UICC-TNM stratification system. There is currently no immune-based classification of...

Cite
Galon J, Lanzi A. Immunoscore and its introduction in clinical practice. Q J Nucl Med Mol Imaging. 2020;64(2):152-161doi: 10.23736/S1824-4785.20.03249-5.
Galon, J., & Lanzi, A. (2020). Immunoscore and its introduction in clinical practice. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 64(2), 152-161. https://doi.org/10.23736/S1824-4785.20.03249-5
Galon, Jérôme, and Lanzi, Anastasia. "Immunoscore and its introduction in clinical practice." The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... vol. 64,2 (2020): 152-161. doi: https://doi.org/10.23736/S1824-4785.20.03249-5
Galon J, Lanzi A. Immunoscore and its introduction in clinical practice. Q J Nucl Med Mol Imaging. 2020 Jun;64(2):152-161. doi: 10.23736/S1824-4785.20.03249-5. Epub 2020 Feb 27. PMID: 32107902.
Copy Download .nbib Format: NLM
How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina.

Social science & medicine (1982)

Roberti J, Alonso JP, Blas L, May C.
PMID: 34952327
Soc Sci Med. 2021 Dec 18;293:114666. doi: 10.1016/j.socscimed.2021.114666. Epub 2021 Dec 18.

BACKGROUND: A new chronic patient has emerged, with a burden of symptoms and treatment. Patients with kidney failure (KF) require complex and expensive treatments, and in underresourced contexts, they struggle to obtain quality and timely care, even in countries...

Cite
Roberti J, Alonso JP, Blas L, et al. How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina. Soc Sci Med. 2021;293:114666doi: 10.1016/j.socscimed.2021.114666.
Roberti, J., Alonso, J. P., Blas, L., & May, C. (2021). How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina. Social science & medicine (1982), 293114666. https://doi.org/10.1016/j.socscimed.2021.114666
Roberti, Javier, et al. "How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina." Social science & medicine (1982) vol. 293 (2021): 114666. doi: https://doi.org/10.1016/j.socscimed.2021.114666
Roberti J, Alonso JP, Blas L, May C. How do social and economic vulnerabilities shape the work of participating in care? Everyday experiences of people living with kidney failure in Argentina. Soc Sci Med. 2021 Dec 18;293:114666. doi: 10.1016/j.socscimed.2021.114666. Epub 2021 Dec 18. PMID: 34952327.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 101 entries